{"nctId":"NCT02065791","briefTitle":"Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy","startDateStruct":{"date":"2014-02-17","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 2","Diabetic Nephropathy"],"count":4401,"armGroups":[{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Canagliflozin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus with a hemoglobin A1c (HbA1c) greater than or equal to (\\>=) 6.5 percent (%) and less than or equal to (\\<=) 12.0%, with an estimated glomerular filtration rate (eGFR) of \\>= 30 milliliter (mL)/minute (min)/1.73meter (m)\\^2 and less than (\\<) 90 mL/min/1.73 m\\^2\n* Participants need to be on a stable maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 4 weeks prior to randomization\n* Must have a urine albumin to creatinine ratio (UACR) of greater than (\\>) 300 milligram (mg)/gram (g) and \\<= 5000 mg/g\n\nExclusion Criteria:\n\n* History of diabetic ketoacidosis or type 1 diabetes mellitus\n* History of hereditary glucose-galactose malabsorption or primary renal glucosuria\n* Renal disease that required treatment with immunosuppressive therapy\n* Known significant liver disease\n* Current or history of New York Heart Association (NYHA) Class IV heart failure\n* Blood potassium level \\>5.5 millimole (mmol)/liter (L) during Screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death","description":"Primary composite endpoint is the composite of DoSC, ESKD, and renal or CV death. DoSC: from baseline average determination (sustained and confirmed by repeat central laboratory measure after at least 30 days and preferably within 60 days). ESKD: as initiation of maintenance dialysis for at least 30 days, or renal transplantation, or an estimated glomerular filtration rate (eGFR) value of less than (\\<)15 milliliters per minute per 1.73 square meter (mL/min/1.73 m\\^2) (sustained and confirmed by repeat central laboratory measure after at least 30 days and preferably within 60 days). Renal death: death in participants who had reached ESKD, died without initiating renal replacement therapy, and no other cause of death was determined via adjudication. Adjudication of these events by Endpoint Adjudication Committee (EAC) was performed in blinded fashion. Event rate estimated based on time to first occurrence of primary composite endpoint are presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.24","spread":null},{"groupId":"OG001","value":"43.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Endpoint of CV Death and Hospitalized Heart Failure (HHF)","description":"The composite endpoint included CV death and HHF. CV death included death due to myocardial infarction (MI), stroke, heart failure, sudden death, death during a CV procedure or as a result of procedure-related complications, or death due to other CV causes. For analytic purposes, undetermined causes of death were considered CV deaths. In determining whether a death event was CV in nature, the EAC took into consideration both the proximate and underlying causes. Adjudication of these events by the EAC was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of the composite endpoint of CV death and HHF are presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.44","spread":null},{"groupId":"OG001","value":"31.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Major Adverse Cardiac Event (MACE)","description":"The composite endpoint included CV death, non-fatal MI, and non-fatal stroke (that is, 3-point MACE). Adjudication of these events by the EAC was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of MACE are presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.67","spread":null},{"groupId":"OG001","value":"38.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospitalized Heart Failure (HHF)","description":"Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of hospitalized heart failure are presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.33","spread":null},{"groupId":"OG001","value":"15.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Renal Composite Endpoint","description":"The renal composite endpoint included composite of DoSC, ESKD and Renal death. DoSC: from the baseline average determination (sustained and confirmed by repeat central laboratory measure after at least 30 days and preferably within 60 days). ESKD: initiation of maintenance dialysis for at least 30 days, or renal transplantation, or an eGFR value of \\<15 mL/min/1.73 m\\^2 (sustained and confirmed by repeat central laboratory measure after at least 30 days and preferably within 60 days). Renal death: death in participants who have reached ESKD, died without initiating renal replacement therapy, and no other cause of death was determined via adjudication. Adjudication of these events by the EAC was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of the renal composite endpoint are presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.36","spread":null},{"groupId":"OG001","value":"26.99","spread":null}]}]}]},{"type":"SECONDARY","title":"Cardiovascular (CV) Death","description":"CV death included death due to MI, stroke, heart failure, sudden death, death during a CV procedure or as a result of procedure-related complications, or death due to other CV causes. For analytic purposes, undetermined causes of death were considered CV deaths. In determining whether a death event was a CV in nature, the EAC took into consideration both the proximate and underlying causes. Adjudication of these events by the EAC was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of CV death are presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.38","spread":null},{"groupId":"OG001","value":"19.01","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality","description":"Adjudication of these events by Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on time to first occurrence of all-cause mortality are presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.00","spread":null},{"groupId":"OG001","value":"29.04","spread":null}]}]}]},{"type":"SECONDARY","title":"CV Composite Endpoint","description":"The CV composite endpoint included the CV death, non-fatal MI, non-fatal stroke, hospitalized heart failure, and hospitalized unstable angina. CV death included death due to MI, stroke, heart failure, sudden death, death during a CV procedure or as a result of procedure-related complications, or death due to other CV causes. For analytic purposes, undetermined causes of death were considered CV deaths. In determining whether a death event was a CV in nature, the EAC took into consideration both the proximate and underlying causes. Adjudication of these events by the EAC was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of the CV composite endpoint are presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.95","spread":null},{"groupId":"OG001","value":"49.35","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":806,"n":2197},"commonTop":["Hypoglycaemia","Urinary Tract Infection","Hypertension","Blood Creatinine Increased","Oedema Peripheral"]}}}